Evidence map›Paper›PMID 42324205›Full record

GuidelineInternational journal of cancer2026

The German ONKOPEDIA Guideline for Myelofibrosis in 2025-Recommendations of an MPN Expert Panel of the German Society for Hematology and Oncology (DGHO).

Martin Griesshammer, Haifa Kathrin Al-Ali, Gabriela M Baerlocher, Konstanze Döhner, Steffen Koschmieder, Nicolaus Kröger, Petro E Petrides, Dominik Wolf, Florian H Heidel

Abstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Martin GriesshammerUniversity Clinic for Hematology, Oncology, Haemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Minden, Germany.
Haifa Kathrin Al-AliKrukenberg Cancer Center, University Hospital of Halle, Halle, Germany.
Gabriela M BaerlocherClinic for Hematology and Oncology, Hirslanden Zürich AG, Zürich, Switzerland.
Konstanze DöhnerDepartment of Internal Medicine III, University Hospital Ulm, Ulm, Germany.
Steffen KoschmiederDepartment of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
Nicolaus KrögerUniversity Clinic for Hematology and Stem Cell Transplantation, Essen, Germany.
Petro E PetridesHematology Oncology Center Munich and Ludwig Maximilians University Munich, Munich, Germany.
Dominik WolfUniversitätsklinik für Innere Medizin V, Innsbruck, Austria.
Florian H HeidelHematology, Hemostasis, Oncology, and Cell Therapy, Hannover Medical School, Hannover, Germany.ORCID https://orcid.org/0000-0003-2438-1955

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The recently published ONKOPEDIA guideline on myelofibrosis, issued under the auspices of the German Society of Hematology and Oncology (DGHO), provides an updated, evidence-based framework for the diagnosis and management of this rare, chronic myeloproliferative neoplasm. Developed by a panel of experts (including Germany, Austria and Switzerland) nominated by the DGHO, the guideline reflects a structured and consensus-oriented process in which internationally recognized specialists in hematology critically reviewed the available evidence, revised the written draft, and engaged in multiple rounds of discussion to ensure consistency, clinical relevance, and scientific rigor. This update builds upon the foundation of the previously available ONKOPEDIA guideline (accessible at www.onkopedia.com), but extends and refines the recommendations in light of several important recent developments.

Indexed as

Myeloproliferative DisordersPrimary MyelofibrosisGermanyHematologyHumansMedical OncologySocieties, MedicalguidelinesMyelofibrosisrecommendation

Identifiers

PMID42324205
PMCPMC13432566

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.